MDxHealth, EHC Innovation Collaborate
News Sep 29, 2016
MDxHealth SA has announced that it has signed a distribution agreement with The European Health Centre Innovation (EHC Innovation) to offer its SelectMDx(TM) for Prostate Cancer and ConfirmMDx® for Prostate Cancer tests to their urology customers throughout Poland.
Under the terms of the agreement, EHC Innovation will be one of two exclusive distributors of SelectMDx in Poland and the only exclusive distributor of ConfirmMDx. Samples will be sent to MDxHealth's clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. EHC Innovation will reimburse MDxHealth for all testing services.
"We are delighted to announce our collaboration with The European Health Centre Innovation which, as part of European Health Center Otwock Hospital, is the most technologically advanced multispecialty diagnostic centre in Poland. We believe that SelectMDx and ConfirmMDx perfectly complement EHC Innovation's existing portfolio of advanced diagnostic tools," commented Dr. Jan Groen, CEO of MDxHealth.
"With a strong reputation throughout the region and focus on improving patient care and outcomes, EHC Innovation is an ideal partner to help us raise awareness and expand access to SelectMDx and ConfirmMDx within the urology community."
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018